[go: up one dir, main page]

EE200100533A - Ateroskleroosi või diabeetilise retionopaatia arenemise riski diagnoosimine isikutel - Google Patents

Ateroskleroosi või diabeetilise retionopaatia arenemise riski diagnoosimine isikutel

Info

Publication number
EE200100533A
EE200100533A EEP200100533A EEP200100533A EE200100533A EE 200100533 A EE200100533 A EE 200100533A EE P200100533 A EEP200100533 A EE P200100533A EE P200100533 A EEP200100533 A EE P200100533A EE 200100533 A EE200100533 A EE 200100533A
Authority
EE
Estonia
Prior art keywords
development
risk
individuals
diagnosis
diseases
Prior art date
Application number
EEP200100533A
Other languages
English (en)
Estonian (et)
Inventor
Koulu Markku
Karvonen Matti
Pesonen Ullamari
Uusitupa Matti
Original Assignee
Hormos Medical Oy Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Oy Ltd. filed Critical Hormos Medical Oy Ltd.
Publication of EE200100533A publication Critical patent/EE200100533A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
EEP200100533A 1999-04-15 2000-03-29 Ateroskleroosi või diabeetilise retionopaatia arenemise riski diagnoosimine isikutel EE200100533A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/291,994 US6312898B1 (en) 1999-04-15 1999-04-15 Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
PCT/FI2000/000260 WO2000063430A1 (en) 1999-04-15 2000-03-29 Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy

Publications (1)

Publication Number Publication Date
EE200100533A true EE200100533A (et) 2002-12-16

Family

ID=23122742

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100533A EE200100533A (et) 1999-04-15 2000-03-29 Ateroskleroosi või diabeetilise retionopaatia arenemise riski diagnoosimine isikutel

Country Status (17)

Country Link
US (2) US6312898B1 (de)
EP (1) EP1169475B1 (de)
JP (1) JP2003521473A (de)
AT (1) ATE316153T1 (de)
AU (1) AU777917B2 (de)
CA (1) CA2363994A1 (de)
CZ (1) CZ20013549A3 (de)
DE (1) DE60025595T2 (de)
EE (1) EE200100533A (de)
ES (1) ES2251977T3 (de)
HU (1) HUP0200719A3 (de)
NO (1) NO20014969D0 (de)
NZ (1) NZ513189A (de)
PL (1) PL350620A1 (de)
RU (1) RU2238107C2 (de)
WO (1) WO2000063430A1 (de)
ZA (1) ZA200104775B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107327A1 (en) * 1997-12-19 2005-05-19 Hormos Medical Corporation Method for reducing overproduction of neuropeptide Y in an individual
PL362862A1 (en) * 2000-03-21 2004-11-02 Hormos Medical Corporation Diagnosis of a person's risk of developing alcoholism
US20040254131A1 (en) * 2003-06-16 2004-12-16 Markku Koulu Method for prevention or treatment of diseases or disorders related to excessive formation of vascular tissue or blood vessels
US6979294B1 (en) * 2002-12-13 2005-12-27 California Institute Of Technology Split-screen display system and standardized methods for ultrasound image acquisition and processing for improved measurements of vascular structures
WO2005052593A1 (en) * 2003-10-29 2005-06-09 The University Of Leicester Detection
KR100961926B1 (ko) * 2007-08-30 2010-06-10 서울대학교산학협력단 당뇨병성 망막병증 검출용 바이오 마커 조성물 및 진단키트
ES2337115B2 (es) * 2007-09-26 2011-01-24 Universidade De Santiago De Compostela Metodo para la deteccion del riesgo de desarrollar vitreorretinopatiaproliferante (vrp).
US20100225239A1 (en) * 2009-03-04 2010-09-09 Purespectrum, Inc. Methods and apparatus for a high power factor, high efficiency, dimmable, rapid starting cold cathode lighting ballast
RU2465598C1 (ru) * 2011-09-07 2012-10-27 Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития диабетической ретинопатии при сахарном диабете типа 2 у якутов
RU2461005C1 (ru) * 2011-09-07 2012-09-10 Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития диабетической ретинопатии при сахарном диабете типа 2 у якуток
RU2533836C1 (ru) * 2013-09-25 2014-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования Воронежская государственная медицинская академия имени Н.Н. Бурденко Министерства здравоохранения Российской Федерации (ГБОУ ВПО ВГМА им. Н.Н. Бурденко Минздрава России) Способ мониторинга лиц с риском раннего развития атеросклероза и наличием сахарного диабета 2 типа

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455164A (en) 1989-11-03 1995-10-03 Mcgill University Ruminant immortalized mammary epithelial cell lines
US5714497A (en) * 1993-02-15 1998-02-03 Sanofi Compounds bearing sulphamoyl and amidino radicals, their preparation process and pharmaceutical compositions containing them
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
GB9708918D0 (en) 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds

Also Published As

Publication number Publication date
AU3563200A (en) 2000-11-02
EP1169475B1 (de) 2006-01-18
US20050234008A1 (en) 2005-10-20
US6312898B1 (en) 2001-11-06
AU777917B2 (en) 2004-11-04
WO2000063430A1 (en) 2000-10-26
ZA200104775B (en) 2002-06-12
NZ513189A (en) 2003-05-30
CZ20013549A3 (cs) 2002-04-17
PL350620A1 (en) 2003-01-27
ATE316153T1 (de) 2006-02-15
NO20014969L (no) 2001-10-12
HUP0200719A2 (en) 2002-06-29
RU2238107C2 (ru) 2004-10-20
DE60025595D1 (de) 2006-04-06
JP2003521473A (ja) 2003-07-15
EP1169475A1 (de) 2002-01-09
CA2363994A1 (en) 2000-10-26
NO20014969D0 (no) 2001-10-12
HUP0200719A3 (en) 2004-11-29
DE60025595T2 (de) 2006-11-16
ES2251977T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
Westman et al. Noise and stress: a comprehensive approach
EE200100533A (et) Ateroskleroosi või diabeetilise retionopaatia arenemise riski diagnoosimine isikutel
EP1409544A4 (de) Humane dr4-antikörper und deren anwendungen
GB0100119D0 (en) Materials and methods relating to protein aggregation in neurodegenerative disease
Dew The cult and science of public health: A sociological investigation
Langthorne et al. Functional analysis of the early development of self-injurious behavior: Incorporating gene–environment interactions
FI933291A0 (fi) Foerfarande foer paovisning av anti-rna-antikroppar
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
Coleman et al. Proposed standards of care for the treatment of adult sex offenders
WOLF et al. Intensive screening for gonorrhea, syphilis, and hepatitis B in a gay bathhouse does not lower the prevalence of infection
BG106583A (en) Diagnosis of a person's risk of developing alcoholism
Tuttman Regression: Is it necessary or desirable?
GB2431348A (en) Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders
Panakal An Agenda for Criminology
O'Reilly et al. A preliminary investigation of the assessment and treatment of tantrums with two post-institutionalized Romanian adoptees
Howard Poor Joshua: The DeShaney case and child abuse in America
D'Alessandro et al. The 5th Amendment of the Declaration of Helsinki: implications for medical research in developing countries
Knopf et al. How family treatment can help break the CPS cycle
Turner Globalizing human-animal companionship
Surarith Women's Struggle for Housing Rights in Thailand
Yoder et al. Influences of disabling conditions on the nature and frequency of farm/ranch-related injuries
Wilson PART VI
Johnson Pediatrician named EPA children's environmental health adviser
LeClair Particulates, ozone standards due July 19
Condon Long term effects of smoking cessation program for cardiac patients...(continuing education credit)